Patoloxía Molecular das Doenzas Raras
PatMol-DR
![Foto de Patoloxía Molecular das Doenzas Raras](/img/grupo.png)
![Foto de Imperial College London](/img/noimage_org.png)
Imperial College London
Londres, Reino UnidoPublicacións en colaboración con investigadores/as de Imperial College London (17)
2024
-
Aggregation-resistant alpha-synuclein tetramers are reduced in the blood of Parkinson’s patients
EMBO Molecular Medicine, Vol. 16, Núm. 7, pp. 1657-1674
2023
-
Changes in circulating ApoJ-Glyc levels in patients with suspected acute coronary syndrome: The EDICA trial
International Journal of Cardiology, Vol. 391
2022
-
ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2-care pathways, treatment, and follow-up
European Heart Journal, Vol. 43, Núm. 11, pp. 1059-1103
-
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis
Cardiovascular research, Vol. 118, Núm. 6, pp. 1385-1412
-
European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1-epidemiology, pathophysiology, and diagnosis
European Heart Journal, Vol. 43, Núm. 11, pp. 1033-1058
2021
-
Empagliflozin in heart failure with a preserved ejection fraction
New England Journal of Medicine, Vol. 385, Núm. 16, pp. 1451-1461
2020
-
Baseline characteristics of patients with heart failure with preserved ejection fraction in the EMPEROR-Preserved trial
European Journal of Heart Failure, Vol. 22, Núm. 12, pp. 2383-2392
-
Proportion of High-Risk/Very High-Risk Patients in Europe with Low-Density Lipoprotein Cholesterol at Target According to European Guidelines: A Systematic Review
Advances in Therapy, Vol. 37, Núm. 5, pp. 1724-1736
2019
-
Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial
The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628
-
Proteomic studies reveal disrupted in schizophrenia 1 as a player in both neurodevelopment and synaptic function
International Journal of Molecular Sciences, Vol. 20, Núm. 1
-
Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a phase 3, placebo-controlled, randomised trial
The Lancet, Vol. 394, Núm. 10204, pp. 1169-1180
2018
-
Alirocumab and cardiovascular outcomes after acute coronary syndrome
New England Journal of Medicine, Vol. 379, Núm. 22, pp. 2097-2107
2017
-
Evolocumab and clinical outcomes in patients with cardiovascular disease
New England Journal of Medicine, Vol. 376, Núm. 18, pp. 1713-1722
2016
-
Prognostic significance of anaemia in patients with heart failure with preserved and reduced ejection fraction: Results from the MAGGIC individual patient data meta-analysis
QJM, Vol. 109, Núm. 6, pp. 377-382
-
The Structural Architecture of an Infectious Mammalian Prion Using Electron Cryomicroscopy
PLoS Pathogens, Vol. 12, Núm. 9
2009
-
Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomised, double-blind trial
The Lancet, Vol. 374, Núm. 9704, pp. 1840-1848
2005
-
Adherence to guidelines is a predictor of outcome in chronic heart failure: The MAHLER survey
European Heart Journal, Vol. 26, Núm. 16, pp. 1653-1659